A license agreement from UCB to Pheno Therapeutics will enable the acceleration of a promising new drug tackling neurological diseases towards clinical development.
The patient recruitment solutions company plans to work with the charity to support research and clinical trials through a range of fundraising activities.
The pharmaceutical firm’s More to uS is a UK-centered campaign that shares stories of people living (and thriving) after a multiple sclerosis diagnosis.
AbbVie is collaborating with MC10 to use its wearable system to gather insights on possible metrics and digital biomarkers that can be applied to MS trials.
The company’s Mavenclad treatment gains approval from the US FDA for the treatment of multiple sclerosis, eight years after it had been initially rejected.
Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
Teva has aggressively defended its market share for its blockbuster Copaxone says Momenta, six months after marketing partner Sandoz launched the first generic version in the US.
in-PharmaTechnologist presents its weekly round-up of the latest appointments in the pharmaceutical industry, including news from SciFluor, NinePoint and Abbott India.
US biotechnology major Genzyme has begun $68m of refurbishment work on a new 211,000 sgft manufacturing and shipping complex in Northborough, Massachusetts.
Teva's sales of active pharmaceutical ingredients (APIs) for the
first quarter of 2008 rose by 51 per cent on the previous years
figure, taking to total to $510m.
Drug delivery specialist Antares Pharma has landed its fourth deal
with Israeli generics behemoth Teva, this time to develop a novel
pen injector for two Teva products.
Bayer Schering Pharma this week announced that it has scrapped
plans to introduce a double-dose version of its top-selling
multiple sclerosis (MS) drug Betaferon (interferon beta-1b) by the
end of the year following disappointing...
Biogen Idec is pushing forward with a therapeutic antibody that can
turn myelin producing cells back on and so could reverse the
damaging effects of multiple sclerosis (MS).
Novartis and Bayer Schering Pharma have finally settled their
disputes over multiple sclerosis (MS) drug Betaseron (interferon
beta-1b), with an agreement outlined in March now complete.
Merck Serono's new and improved version of its blockbuster multiple
sclerosis (MS) drug Rebif (interferon beta-1a) has been approved in
the EU, providing a little added protection to the company's MS
franchise.
With a number of companies competing in the race to develop the
first oral treatment option for multiple sclerosis, UCB and Biogen
Idec's oral version of the infamous Tysabri has entered Phase II
trials.
A joint effort to develop a winning oral formulation for the
treatment of multiple sclerosis (MS) has taken another step towards
the finish line with initiation of Phase III trials for the novel
laquinimod compound.
Novartis and Bayer Schering Pharma have come to an agreement
regarding the production of multiple sclerosis (MS) drug Betaseron
(interferon beta-1b), with Novartis planning to bring out its own
version in 2009 and Bayer paying around...
Researchers have developed a more efficient and cost-saving method
to make cladribine, a drug used for the treatment of certain types
of leukaemia and potentially efficient against multiple sclerosis
(MS).
Researchers believe that a genetic discovery involving a cellular
signal that aggravates the symptoms of MS may be a viable target in
new therapeutic approaches, which could alleviate the burden of
this debilitating neurological disease.
AppTec Laboratory Services has signed a new contract to manufacture
Chromos Molecular Systems's new multiple sclerosis (MS) drug for
pre-clinical safety and toxicology studies.
A new laboratory method, which looks for a spinal fluid protein,
may identify people with the earliest stages of multiple sclerosis
(MS), greatly increasing the effectiveness of drug therapies to
treat the 10,000 Americans, who are...
Serono has announced a mixed third quarter 2005 with product sales
and total revenues weaker than predicted. Its net income beat
market consensus but the company was hit by an $18.3 million (€15.2
million) one-off charge related to...
The interest in Syntonix' SynFusion and Transceptor technologies
intensified as Boehringer Ingelheim became the second
pharmaceutical company to use this technology to optimise its
therapeutic peptides for inhalation.
German pharmaceutical firm, Schering took the opportunity, during
the company’s annual financial meeting, to provide an update on its
drug development pipeline, which concentrates on the disease areas
of hormonal therapies, cancer...
Teva Pharmaceutical Industries' active pharmaceutical ingredients
(API) business is on track to become a $1 billion enterprise this
year, although growth in the first quarter of this year was almost
entirely from in-house sales,...
Researchers have identified a common gene variant that could be a
risk factor behind a number of common diseases such as
cardiovascular disease, rheumatism and Multiple Sclerosis (MS), of
which up to a quarter of the population could...
Serono and Syntonix Pharmaceuticals announced today that they have
entered into an agreement that allows Serono the exclusive rights
to use Syntonix' Transceptor and Synfusion technologies for the
development and commercialisation...
Researchers at the Serono Genetics Institute have announced the
identification of 80 genes involved in the inflammatory and
neuro-degenerative pathways of multiple sclerosis (MS) forming a
library of potential targets for future treatments...
The first in a completely new class of drug for multiple sclerosis
has been approved in the US, opening up a new avenue of treatment
for sufferers of the debilitating diseases and potential
blockbuster revenues for developers Elan...
Switzerland's Serono, Europe's largest biotechnology company, has
said it will close its InterPharm manufacturing plant in Ness
Ziona, Israel, by the end of year.
Serono has unveiled a $200 million (€168m) investment in an Israeli
facility that will be used to produce Rebif, the company's drug
treatment for multiple sclerosis.
US biotechnology company Biogen has decided to postpone
construction of a large production plant at Hillerød in Denmark,
just three months after breaking ground on the facility